elotuzumab
Selected indexed studies
- Elotuzumab. (, 2006) [PMID:29999843]
- Elotuzumab. (, 2012) [PMID:31644037]
- Elotuzumab in multiple myeloma. (Expert Opin Biol Ther, 2023) [PMID:36373842]
_Worker-drafted node — pending editorial review._
Connections
elotuzumab is a side effect of
Sources
- Elotuzumab. (2006) pubmed
- Elotuzumab. (2012) pubmed
- Elotuzumab in multiple myeloma. (2023) pubmed
- Elotuzumab for multiple myeloma. (2022) pubmed
- The Clinical Pharmacology of Elotuzumab. (2018) pubmed
- Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma. (2018) pubmed
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. (2023) pubmed
- Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. (2019) pubmed
- Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. (2024) pubmed
- Elotuzumab: First Global Approval. (2016) pubmed